StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Dabigatran Etexilate Mesylate

HCID 135566083
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
872728-81-9
Standard-SMILES
CCCCCCOC(=O)NC(=N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1.CS(=O)(=O)O
InChIKey
XETBXHPXHHOLOE-UHFFFAOYSA-N
Summenformel
C35H45N7O8S
Durchschnittliche Molmasse
723,8 g/mol

Überblick

Dabigatran Etexilate Mesylate is an orally available mesylate salt form of the etexilate prodrug of dabigatran, a benzimidazole and direct thrombin inhibitor with anticoagulant activity. Upon administration, dabigatran etexilate is hydrolyzed by esterases and is converted into dabigatran. Dabigatran reversibly binds to and inhibits the activity of thrombin, a serine protease that converts fibrinogen into fibrin. This disrupts the coagulation cascade and inhibits the formation of blood clots.

Namen und Bezeichner

Bevorzugter Name
Dabigatran Etexilate Mesylate
IUPAC
ethyl 3-[[2-[[4-(N-hexoxycarbonylcarbamimidoyl)anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate;methanesulfonic acid
Englischer Name
Dabigatran Etexilate Mesylate
Summenformel
C35H45N7O8S
Molmasse
723.85

Namen und Synonyme

Dabigatran etexilate mesylate872728-81-9Dabigatran etexilate mesilatePradaxaDabigatran etexilate methanesulfonateBIBR 1048 MSSC7NUW5IITBIBR 1048MSBIBR-1048-MSPRADAXA (DABIGATRAN ETEXILATE MESYLATE)Ethyl 3-(((2-(((4-(((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-1h-benzimidazol-5-yl)carbonyl)(pyridin-2-yl)amino)propanoate, methanesulfonatebeta-Alanine, N-((2-(((4-((((hexyloxy)carbonyl)amino)iminomethyl)phenyl)amino)methyl)-1-methyl-1h-benzimidazol-5-yl)carbonyl)-N-2-pyridinyl-, ethyl ester, methanesulfonate
Weitere Namen anzeigen
Dabigatran mesylateDabigatran Etexilate Mesylate APIEthyl 3-(2-(((4-(N-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-Hexyl 2-(4-(((5-((3-ethoxy-3-oxopropyl)(pyridin-2-yl)carbaMoyl)-1-Methyl-1H-benzo[d]iMidazol-2-yl)Methyl)aMino)benzylidene)hydrazinecarboxylate Methanesulfonateethyl 3-(2-(((4-(N-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate methanesulfonate

Eigenschaften

Berechnete Struktureigenschaften

Polarare Oberfläche (TPSA)
214 Ų
H-Brücken-Donoren
4
H-Brücken-Akzeptoren
12
Frei drehbare Bindungen
18
Schwere Atome
51
Formalladung
0
Komplexität
1.080

Experimentelle und physikochemische Eigenschaften

Human Drugs · 3 Einträge

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Physikochemische Eigenschaften

Schmelzpunkt
125 °C · >125°C
storage temp.
Refrigerator
Löslichkeit
DMSO (Slightly, Heated), Methanol (Slightly)
Aggregatzustand
Solid
Farbe
White to Pale Yellow
Major Application
pharmaceutical
InChIKey
XETBXHPXHHOLOE-UHFFFAOYSA-N
SMILES
S(O)(=O)(=O)C.CN1C(=NC2C=C(C(=O)N(C3N=CC=CC=3)CCC(=O)OCC)C=CC1=2)CNC1C=CC(C(=N)NC(=O)OCCCCCC)=CC=1

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H361 (50%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]

P203, P260, P263, P264, P270, P273, P280, P318, P319, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 4 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Hazard Classes and CategoriesRepr. 2 (50%)

Toxikologische Informationen

Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Dabigatran etexilate mesylate

vLess-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Sicherheitsdaten

wgk
WGK 3
Speicherklasse
11 - Combustible Solids

Chemie und Industrie

Pharmakologische Informationen

FDA Pharmacological Classification · 2 Einträge

DABIGATRAN ETEXILATE MESYLATE

Direct Thrombin Inhibitor [EPC]; Thrombin Inhibitors [MoA]

MeSH Pharmacological Classification · 1 Eintrag

Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins.

Anwendungen · 2 Einträge

HistoryDabigatran Etexilate Mesylate (brand name pradaxa) was discovered from a panel of chemicals with similar structure to benzamidine-based thrombin inhibitor α-NAPAP (N-alpha-(2-naphthylsulfonylglycyl)-4-amidinophenylalanine piperidide). Addition of ethyl ester and hexyloxycarbonyl carbamide hydrophobic side chains led to the orally absorbed prodrug, BIBR 1048 (dabigatran etexilate).In March 2008, the European Medicines Agency (EMA) granted marketing authorization for Pradaxa for the prevention of thromboembolic disease following hip or knee replacement surgery and for non-valvular atrial fibrillation.The National Health Service (NHS) in Britain authorized dabigatran for use in preventing blood clots in hip and knee replacement surgery patients. Pradaxa received a Notice of Compliance (NOC) from Health Canada in June 2008,[45] for the prevention of blood clots in patients who have undergone total hip or total knee replacement surgery. Approval for atrial fibrillation patients at risk of stroke came in October 2010.The U.S. Food and Drug Administration (FDA) approved Pradaxa in October 2010, for prevention of stroke in patients with non-valvular atrial fibrillation.In February 2011, the American College of Cardiology Foundation and the American Heart Association added dabigatran to their guidelines for management of non-valvular atrial fibrillation with a class I recommendation.

VerwendenNonpeptide, direct thrombin inhibitor. Antithrombotic.

Vor- und nachgelagerte Produkte

Zugehörige Reaktionen

1
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 1805896
HRID 1805896als Produkt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
(E)-hexyl 2-(4-((5-((3-ethoxy-3-oxopropyl)(pyridin-2-yl)carbaMoyl)-1-Methyl-1H-benzo[d]iMidazol-2-yl)MethylaMino)benzylidene)hydrazinecarboxylate Methanesulfonate
N-[[2-[[[4-[[[(Hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-beta-alanine ethyl ester monomethanesulfonat
Dabig
593282-20-3CHEBI:70743DTXSID20236248RefChem:54925DTXCID20158739Beta-alanine, N-((2-(((4-((((hexyloxy)carbonyl)amino)iminomethyl) phenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)-N-2-pyridinyl-,ethyl ester, methanesulfonatePradaxa mesylateDabigatran etexilate (mesylate)

Datenbank-Bezeichner

CAS
872728-81-9
PubChem CID
135566083
ChEMBL
CHEMBL1615369
UNII
SC7NUW5IIT
EC Number
828-727-6

Vorgelagerte Rohstoffe

Dabigatran etexilateMethansulfonsure
Ergänzende Hinweise · 1 Eintrag

DefinitionChEBI: A methanesulfonate salt obtained by reaction of dabigatran etexilate with one equivalent of dabigatran etexilate. A prodrug for dabigatran, a thrombin inhibitor and anticoagulant which is used for the prevention of stroke and systemic embolism.